The historic rise of Viagra has firmly established as a benchmark of pharmaceutical success, yet its position within the broader industry now triggers questions about long-term gains. Alternative versions are eroding exclusivity , causing anxieties that betting on companies closely tied to Viagra's former influence could be a speculative decision ,